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Purpose: Accurate indications and the extent of surgery for branch duct intraduct-
al papillary mucinous neoplasm (IPMN) of the pancreas are still debatable. In par-
ticular, small tumor is located at the head portion of pancreas presents a dilemma. 
The purpose of this study is to compare the efficacy of enucleation (EN) with that 
of pancreaticoduodenectomy (PD) in patients with small (2 cm<size<3 cm) 
branch duct IPMN located at the head of pancreas or uncinate process. Materials 
and Methods: Among 155 patients who underwent pancreatic surgery due to pan-
creatic cystic tumors between January 2000 and December 2007 at Yonsei Univer-
sity Health System in Seoul, Korea, 14 patients with small (2 cm<size<3 cm) 
branch duct IPMN located at the head of pancreas or uncinate process were in-
cluded in this study. Ten patients underwent PD, and four patients underwent EN. 
We compared short term surgical outcomes between the two groups. Correlation 
of the variables was analyzed using Mann-Whitney test and Fisher’s exact test 
(SPSS Window 12.0). p-values less than 0.05 were considered significant. Re-
sults: The average age was 62.21 years (±6.71 years) and consisted of 8 men and 
6 women. The mean operation time and blood loss were significantly lower in EN 
group. There were no significant differences in other surgical morbidities. Conclu-
sion: The result suggests that enucleation for small branch duct IPMN located at 
the head of pancreas or uncinate process is feasible and as safe as PD, despite a 
high rate of minor complications.
Key Words:    Intraductal papillary mucinous neoplasm, enucleation, pancreatico-
duodenectomy, pancreas head
INTRODUCTION
Thanks to the development of diagnostic tools, intraductal papillary mucinous neo-
plasm (IPMN) of the pancreas has increasingly been detected in asymptomatic pa-Enucleation for IPMN
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was no mural nodule on imaging studies. We did not rou-
tinely perform Endoscopic Ultrasonography Fine Needle 
Aspiration. We determined surgery and the type of surgery 
according to tumor size, presence of mural nodule, and dis-
tance between tumor and main pancreatic duct (not abutting 
to the main pancreatic duct). Pathologic diagnoses were pro-
vided by an expert pathologist and all patients were closely 
followed until December 2008. All patients were followed 
up for more than 12 months, and the mean duration of fol-
low up was 53.57 months (range: 12 to 129).
The patients were divided into two groups according to 
the type of surgery: PD group and EN group. The two groups 
were compared in terms of age, gender, size of tumor, pathol-
ogy, short term surgical outcomes such as operation time, 
blood loss, length of hospital stay, complications, operative 
mortality, and tumor recurrence.
Statistical analysis 
Correlation of the variables was analyzed using Mann-Whit-
ney test and Fisher’s exact test (SPSS Window 12.0). p-values 




This study included 8 male and 6 female patients. Their aver-
age age was 62.21 years (±6.71 years). There was no signifi-
cant difference in age, gender, size of tumor and pathology 
between the two groups (Table 1). However, tumor size was 
significantly larger in the EN group than the PD group.
The mean operation time and intraoperative blood loss 
were significantly less in the EN group than the PD group. 
Both the length of hospital stay and time to normal intake 
of soft diet were shorter in the EN group, but there was no 
statistical significance (Table 2).
Postoperative complications occurred in 2 of 4 patients in 
the EN group, acute pancreatitis in 1 patient (amylasemia, 
no clinical symptoms) and delayed gastric emptying in 1 
patient (Table 3). There was no operative mortality in either 
groups. 
The average follow up period was 43.25 months (range: 
12 to 112) in the EN group, and 57.70 months (range: 13 to 
129) in the PD group. In the latter group, a single case with 
borderline IPMN lesions recurred in the remnant pancreas 
96 months after PD. The patient refused surgery, and we 
decided to observe the lesions.
tients.1-3 A branch duct IPMN smaller than 3 cm should 
sometimes be considered as an indication for surgical resec-
tion, even though it is associated with a lower risk of malig-
nancy.4 Since the malignant risk of small branch duct IPMNs 
is uncertain, it is difficult for surgeons to determine the 
treatment modality, especially if the lesion is located at the 
head of pancreas or uncinate process.
Possible surgical modalities for a branch duct IPMN at 
the pancreatic head include pancreaticoduodenectomy (PD), 
pylorus preserving PD (PPPD), duodenum preserving pan-
creatic head resection, and enucleation. PD is recommend-
ed whenever there is a doubt for the presence of malignant 
risks. However, it is difficult to accurately diagnose the pres-
ence of carcinoma in situ or invasive carcinoma for IPMN 
on preoperative imaging study. Thus, indications and extent 
of surgery for branch duct IPMN of the pancreas are still 
debatable. For branch duct IPMNs with a borderline risk of 
malignancy, a limited resection (duodenum preserving pan-
creatic head resection or enucleation) can be applied with 
less invasiveness. However, duodenum preserving pancre-
atic head resection is technically more demanding than PD. 
Numerous studies have examined the feasibility of surgical 
resection of a small branch duct IPMN, however, most of 
them have focused only on organ preserving pancreatic re-
section.5-7 We, therefore, compared the efficacy of enucle-
ation with that of PD in patients with small (2 cm<size<3 





This study, including the retrospective chart review and data 
collection, was approved by the Institutional Review Board 
of Yonsei University. We retrospectively reviewed 155 pa-
tients who underwent pancreatic surgery for cystic lesions 
in the pancreas between January 2000 and December 2007 
at the Department of Surgery, Yonsei University College of 
Medicine. 
Among these patients, 14 patients who had branch duct 
type IPMN at the pancreatic head and uncinate portion 
with sizes between 2 cm and 3 cm were selected for the 
study. Among them, 10 patients underwent PD or PPPD, 
and 4 underwent enucleation. In the enucleation group (EN 
group), the tumor was located away from the main pancre-
atic duct, not abutting to the main pancreatic duct and there Ho Kyoung Hwang, et al.
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Numerous factors are involved in deciding between sur-
gical treatment or observation with routine radiologic check 
up for the management of small branch duct IPMN, such as 
the presence of mural nodule, tumor size, tumor location, 
age-specific life expectancy for benign cysts, and type of 
surgery. If the branch duct IPMN is located at the body or 
tail of the pancreas, there should be no hesitation in select-
ing a left side pancreatectomy with relatively low rate of 
morbidity than PD. A dilemma in selecting treatment mo-
dality arises if small branch IPMN lesions smaller than 3 
cm are located at the head or uncinate process of pancreas. 
The natural course of small branch duct IPMN over time 
has not been well evaluated. Therefore, many surgeons have 
argued over an aggressive approach to the surgical manage-
ment of pancreatic IPMNs. Recently, clinicians have recom-
mended a more conservative approach.10 However, the ma-
lignancy potential of such lesions has been reported to range 
DISCUSSION
Pancreatic cystic lesions are increasingly identified due to 
several factors, including better quality of diagnostic tools, 
increasing routine physical check-ups, and increasing life 
span. Many studies correlating size and malignancy risk 
have revealed that small branch duct IPMNs are less likely 
to be malignant. A recent consensus conference recommend-
ed follow up every 3-6 months for lesions larger than 20 mm.8 
However, based on results of a large-scale study on branch 
duct IPMNs in Korea,9 our institutional policy has been 
changed to perform surgical exploration for patients with 
lesions ≥2 cm in diameter. In this study, 1 patient (7.1%) 
had malignant lesions, which is in accordance with the re-
sults of other series that reported malignancy rates ranging 
between 6-46% in small branch duct IPMNs.8,9
Table 1. Patient Characteristics according to Type of Operation on Small Branch Duct Intraductal Papillary 
Mucinous Neoplasms of the Pancreatic Head Portion
Variables PD group (n=10) EN group (n=4) p value
Age, yr (mean±SD) 62.70±6.53 61.00±8.04 0.831
Sex (M : F), n 7 : 3 1 : 3 0.245
Tumor size, cm (mean±SD)   2.48±0.44   3.00±0.00 0.032
Incidental finding, n (%)   4 (40.0%)   4 (100%) 0.085
Pathology 1.000
    Adenoma   3 (30.0%)   1 (25.0%)
    Borderline   7 (70.0%)   3 (75.0%)
PD, pancreaticoduodenectomy; EN, enucleation.
Table 2. Surgical Outcomes according to Type of Operation on Small Branch Duct Intraductal Papillary Muci-
nous Neoplasms of Pancreatic Head Portion
Variables PD group (n=10) EN group (n=4) p value
Operation time (min) 371.00±81.74 245.00±26.45 0.007
Soft diet intake (days) 17.10±6.59   15.00±11.22 0.523
Blood loss (mL)   670.00±355.27 100.00±81.64 0.005
Length of stay (days)   34.00±16.43   32.30±18.78  0.321
PD, pancreaticoduodenectomy; EN, enucleation.
Table 3. Morbidity and Mortality according to Type of Operation on Small Branch Duct Intraductal Papillary 
Mucinous Neoplasms of the Pancreatic Head Portion 
PD group (n=10) EN group (n=4) p value
Complications, n (%) 5 (50%) 2 (50%) 1.000
    Pancreatic leakage 2 (20%) 0
    Pancreatitis 0 1 (25%)
    DGE 1 (10%) 1 (25%)
    Intra-abdominal fluid collection 1 (10%) 0
    Postoperative bleeding  1 (10%) 0
Recurrence, n (%) 1 (10%) 0 1.000
Mortality, n (%) 0 0
PD, pancreaticoduodenectomy; EN, enucleation; DGE, delayed gastric emptying.Enucleation for IPMN
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low up required for unconfirmed cystic lesions is socially-
economically expensive. Moreover, there is a time depen-
dent risk of malignant or invasive carcinoma throughout the 
adenoma-carcinoma sequence. This study suggests that enu-
cleation for small  (2 cm<size<3 cm) branch duct IPMNs at 
the pancreatic head portion in asymptomatic patients could 
be feasible, and as safe as PD, despite a high rate of minor 
complications. The procedure may yield accurate diagnosis 
in uncertain cases preoperatively and the ability to treat the 
disease when management is still possible before progression 
to invasive carcinoma. Since this study included a very limit-
ed number of enucleation cases, more experience and long 
term surveillance for enucleation group should be followed.
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